Phase II and Biomarker Study of Cabozantinib in Metastatic Triple‐Negative Breast Cancer Patients
Oncologist - United States
doi 10.1634/theoncologist.2016-0229
Full Text
Open PDFAbstract
Available in full text
Date
January 1, 2017
Authors
Publisher
Alphamed Press